Quest Diagnostics SVP sells 11,717 common shares

Q: How many DGX shares did Patrick Plewman sell, and at what price?

Patrick Plewman sold 11,717 Quest Diagnostics common shares at $257.34 per share on November 9, 2026. The reported exercises and sales were effected pursuant to Rule 10b5-1 sales plans adopted by the reporting person.

Q: How did Patrick Plewman's DGX stock options vest?

The options vested in three equal annual installments, beginning on the first annual anniversary of the grant date.

Available on EDGAR 11/12/2026 - 07:14 PM EST Accepted by SEC EDGAR 11/12/2026 - 07:13 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Very Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Quest Diagnostics Inc. SVP for Diagnostic Services Patrick Plewman exercised options for 4,274 shares at $127.725 and 6,793 shares at $127.805 on November 9, 2026, and sold 11,717 common shares at $257.34 per share. The reported exercises and sales were effected pursuant to Rule 10b5-1 sales plans adopted by Plewman. The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Plewman Patrick

Role SVP for Diagnostic Services

Sold 11,717 shs ($3.02M)

Approx. gross sale proceeds $3.02M

Approx. exercise cost $1.41M

Type	Security	Shares	Price	Value
Exercise	Non-Qualifed Stock Option (right to buy) ^{F1, F3}	4,274	$127.725	$546K
Exercise	Non-Qualifed Stock Option (right to buy) ^{F1, F3}	6,793	$127.805	$868K
Exercise	Common Stock ^F1	4,274	$127.725	$546K
Sale	Common Stock ^F1	4,274	$257.34	$1.10M
Exercise	Common Stock ^F1	6,793	$127.805	$868K
Sale	Common Stock ^F1	6,793	$257.34	$1.75M
Sale	Common Stock ^F2	650	$257.34	$167K

Holdings After Transaction: Non-Qualifed Stock Option (right to buy) — 3,397 options (Direct); Common Stock — 14,684 shares (Direct)

Footnotes (3)

F1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
F2. The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
F3. The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.

Key Figures

Common shares sold: 11,717 shares Sale price: $257.34 per share Options exercised: 4,274 shares +4 more

7 metrics

Common shares sold 11,717 shares November 9, 2026

Sale price $257.34 per share Common shares sold on November 9, 2026

Options exercised 4,274 shares November 9, 2026; exercise price $127.725 per share

Option exercise price $127.725 per share Options for 4,274 shares exercised on November 9, 2026

Options exercised 6,793 shares November 9, 2026; exercise price $127.805 per share

Option exercise price $127.805 per share Options for 6,793 shares exercised on November 9, 2026

Additional common shares sold 650 shares November 9, 2026, at $257.34 per share

Key Terms

Rule 10b5-1 sales plan, Non-Qualifed Stock Option

2 terms

Rule 10b5-1 sales plan regulatory

"effected pursuant to a Rule 10b5-1 sales plan"

Non-Qualifed Stock Option financial

"Non-Qualifed Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many DGX shares did Patrick Plewman sell, and at what price?

Patrick Plewman sold 11,717 Quest Diagnostics common shares at $257.34 per share on November 9, 2026. The reported exercises and sales were effected pursuant to Rule 10b5-1 sales plans adopted by the reporting person.

How did Patrick Plewman's DGX stock options vest?

The options vested in three equal annual installments, beginning on the first annual anniversary of the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plewman Patrick

(Last)

(First)

(Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS

NEW JERSEY

07094

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP for Diagnostic Services

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/09/2026		M⁽¹⁾		4,274	A	$127.725	19,608	D
Common Stock	11/09/2026		S⁽¹⁾		4,274	D	$257.34	15,334	D
Common Stock	11/09/2026		M⁽¹⁾		6,793	A	$127.805	22,127	D
Common Stock	11/09/2026		S⁽¹⁾		6,793	D	$257.34	15,334	D
Common Stock	11/09/2026		S⁽²⁾		650	D	$257.34	14,684	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualifed Stock Option (right to buy)	$127.725	11/09/2026		M⁽¹⁾			4,274	⁽³⁾	02/24/2032	Common Stock	4,274	$127.725	0	D
Non-Qualifed Stock Option (right to buy)	$127.805	11/09/2026		M⁽¹⁾			6,793	⁽³⁾	02/14/2034	Common Stock	6,793	$127.805	3,397	D

Explanation of Responses:

1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

2. The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

3. The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.

Remarks:

	Sean D. Mersten, Attorney in Fact for Patrick Plewman	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR